We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tyratech (DI) | LSE:TYRU | London | Ordinary Share | COM SHS USD0.001 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 2.80 | 3.20 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMTYR TIDMTYRU
RNS Number : 3980A
TyraTech, Inc.
28 December 2017
For immediate release: 28 December 2017
TYRATECH, INC.
("TyraTech" or the "Company")
Result of Special Meeting
Sale of Vamousse
TyraTech Inc. (AIM: TYR, and TYRU), the life sciences company focused on nature-derived insect and parasite control products, announces that at the Special Meeting which was held at 3.00 p.m. (EST) on 27 December 2017 at the Company's principal offices, 5151 McCrimmon Parkway, Suite 275, Morrisville NC 27560 USA, the resolution was duly passed.
As a result, the Company is pleased to announce that the sale of its human lice products brand Vamousse(R) to Alliance Pharma PLC (AIM: APH) ("Alliance") for an initial cash consideration of $13 million with further payments of up to $4.5 million based on the achievement of agreed sales performance targets for Vamousse(R) in 2019 and 2020, will now proceed with immediate effect. TyraTech was advised by Oriole Advisors on the sale.
Following the sale, TyraTech intends to focus on the opportunities within the estimated $6 billion addressable animal health market for control of insects and parasites, a sector in which it already has considerable management experience and new products in commercial stages.
-ends-
For further information:
TyraTech Inc. Tel: +1 919 415 Bruno Jactel, Chief Executive 4340 Officer Tel: +1 919 415 Erica H. Boisvert, Chief Financial 4287 Officer www.tyratech.com SPARK Advisory Partners Limited Tel: +44 20 3368 (Nominated Adviser) 3551 Matt Davis / Mark Brady Allenby Capital Limited (Broker) Tel: +44 20 3328 Chris Crawford 5656 Belvedere Communications (PR) Tel: +44 20 3567 John West / Kim van Beeck 0510
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMEAEAXALKXFAF
(END) Dow Jones Newswires
December 28, 2017 02:00 ET (07:00 GMT)
1 Year Tyratech (DI) Chart |
1 Month Tyratech (DI) Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
